GreyBird Ventures invests in and helps to build companies that solve critical diagnostic problems in precision medicine. Our unique and singular focus allows us to partner with entrepreneurs that meet our stringent criteria from the hundreds of new technologies coming to us from around the world.
Beginning with our first investment in early 2016, each GreyBird company has the potential to dramatically change the standard of care and improve patient health.
Neuromuscular disorders are currently diagnosed by infrequent and often non-quantitative clinical observations of motion. Drug discovery and treatment protocols rely on the subjective response to “How are you doing now?” – the opposite of precision.
The Atlas5D Echo is a sensor that quantifies motion, with high precision in the home without using video or necessitating that anything be worn. With two granted patents, it uses machine learning for motion biomarker discovery to precisely measure disease progression.
While already receiving revenues from trials with two pharmaceutical companies, the GreyBird investment will allow Atlas5D to fully develop their technology and begin to gather the world’s largest precision motion biomarker database for multiple diseases.
Detecting disease from blood suffers from either a lack of specificity (elevated PSA means you “may” have prostate cancer), or a lack of sensitivity in early stages of disease. New DNA-based liquid biopsies, while accurate, mostly detect cancers after stage 3 when cure rates plummet.
Hummingbird Diagnostics, has over 7000 clinical samples tested and 13 granted patents in microRNA diagnostics. Their carefully engineered methodology has demonstrated sensitivity and specificity of over 90% in early stage cancers and neurodegenerative disorders.
While already receiving revenues from grants and pharmaceutical trials, the GreyBird investment will fund large clinical trials in the USA and Europe for early stage lung cancer detection. If the initial results are replicated in the larger trial, it could mean millions of lives saved through early diagnosis.
Precision Medicine Diagnostics requires a test that has both high sensitivity and high specificity. Unfortunately, biomarkers that are highly specific are often low in abundance – especially in the early stages of disease.
The Ceres Nanotrap® technology, protected by 13 issued patents, increases the concentration of targeted biomarkers 10 to 1000 times. It not only captures, concentrates, and preserves the targeted biomarker, it allows detection in urine or saliva.
Continuing to benefit from non-dilutive grant funding (> $6M from DARPA, Gates Foundation, etc.), the GreyBird investment will be used for their first product – a highly sensitive and very specific test for Lyme Disease using a self-collected urine sample.
is named after the arctic tern, a bird that migrates 71,000 km annually. As they can live for 30 years, this is the lifetime equivalent of three trips to the moon and back. Not bad for a 100 gram bird. We strive to emulate its size to performance ratio as well as its global reach.
GreyBird Ventures LLC (“GreyBird”) has prepared the contents of this web site (“Site”) solely for informational purposes and to assist prospective investors who view this Site (the “Recipients”) in deciding whether to proceed with a further investigation of investments managed by GreyBird. Under no circumstances shall this Site be deemed or construed to be an offer to sell, or the solicitation of an offer to buy, any securities, and it is not intended to be the basis of any investment decision or any decision to subscribe to a GreyBird investment vehicle (“Investments”). GreyBird does not make any representation or warranty, expressed or implied, as to the accuracy or completeness of information on the Site.
This Site contains certain statements and estimates made by GreyBird with respect to the anticipated future performance of its Investments and portfolio companies. Such statements and estimates reflect various assumptions concerning anticipated results, which assumptions may or may not prove to be correct. No representations or warranties are made as to the accuracy of such statements or estimates. This Site is for information only and intended for persons reasonably believed to have sufficient expertise to understand the risks involved.
Past performance is not necessarily indicative of future results, and there can be no assurance that the Investments will achieve comparable results or that GreyBird will be able to implement its strategy or achieve its investment objectives. This Site does not constitute an offer to sell or the solicitation of an offer to buy in any state or other U.S. or non-U.S. jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such state or jurisdiction. This offering does not constitute an offer of interests in the investment programs managed by GreyBird (the “Interests”) to the public, and no action has been or will be taken to permit a public offering in any jurisdiction where action would be required for that purpose. The Interests may not be offered or sold, directly or indirectly, and contents of this site may not be copied, reproduced, and/or distributed in any jurisdiction, except in accordance with the legal requirements applicable in such jurisdiction. Prospective investors should inform themselves as to the legal requirements and tax consequences within the countries of their citizenship, residence, domicile and place of business with respect to the acquisition, holding or disposal of Interests, and any non-U.S. exchange restrictions that may be relevant thereto.
Moreover, certain information contained in this Site constitutes “forward-looking” statements, which can be identified by the use of forward-looking terminology such as “may”, “will”, “seek”, “should”, “expect”, “anticipate”, “project”, “estimate”, “intend”, “continue”, “target”, or “believe” or the negatives thereof or other variations thereon or comparable terminology. Due to various risks and uncertainties, including those set forth herein, actual events or results, projected market conditions, interest rate movements, or consumer or investing trends, the actual performance of the Investments may differ materially from that which is reflected or contemplated in such forward-looking statements.
THE INTERESTS HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), THE SECURITIES LAWS OF ANY STATE OR ANY OTHER APPLICABLE SECURITIES LAWS IN RELIANCE UPON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND SUCH LAWS. SUCH INTERESTS MUST BE ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE OFFERED FOR SALE, PLEDGED, HYPOTHECATED, SOLD, ASSIGNED OR TRANSFERRED AT ANY TIME EXCEPT IN COMPLIANCE WITH (I) THE SECURITIES ACT, ANY APPLICABLE STATE SECURITIES LAWS, AND ANY OTHER APPLICABLE SECURITIES LAWS; AND (II) THE TERMS AND CONDITIONS OF THE RELEVANT OPERATING AGREEMENT GOVERNING THE INVESTMENT. THE INTERESTS MAY NOT BE TRANSFERRED OF RECORD EXCEPT IN COMPLIANCE WITH SUCH LAWS AND SUCH OPERATING AGREEMENT. THEREFORE, PURCHASERS OF SUCH INTERESTS WILL BE REQUIRED TO BEAR THE RISK OF THEIR INVESTMENT FOR AN INDEFINITE PERIOD OF TIME.